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ScienceDirectAmong the targets for the development of new antibacterial
agents, bacterial topoisomerases remain a vibrant area of
discovery. A structurally diverse set of inhibitors that bind to the
adenosine 50-triphosphate (ATP) site of type II topoisomerases
have been disclosed recently. Seven compounds with this
mechanism are highlighted, focusing on antibacterial potency
and spectrum, as well as examples of in vivo efficacy against
pathogens including Staphylococcus aureus and
Mycobacterium tuberculosis. Five compounds from two
structural classes are exemplified that are inhibitors that bind to
the catalytic site of DNA gyrase and topoisomerase IV. The
pharmacokinetic and pharmacodynamic properties of these
molecules, derived from in vivo efficacy against Gram-positive
and Gram-negative pathogens, define the potential for these
agents with broad-spectrum and targeted-spectrum clinical
utilities.
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Introduction
Bacterial topoisomerases remain an attractive target for
the discovery and development of new antibacterial
agents. Already the target of the successful fluoroquino-
lone class, new compounds with differentiated mechan-
isms of inhibition against these enzymes continue to be
discovered. This review will focus on disclosures from the
past two years with emphasis on compounds that display
efficacy in animal models of infection, and their under-
lying microbiological, pharmacokinetic, and pharmaceu-
tical properties.
Topoisomerase enzymes control the topological state of
DNA within cells and are critical for the essential pro-
cesses of protein translation and cell replication. TheCurrent Opinion in Pharmacology 2014, 18:76–83 types and functions of bacterial topoisomerases have been
reviewed elsewhere [1,2]. In particular, the type II topoi-
somerases of DNA gyrase and topoisomerase IV have
received the most attention for antibacterial drug discov-
ery. Gyrase and topoisomerase IV share high structural
and sequence similarity, yet play distinct required roles in
DNA replication. Several recent reviews chronicle drug
discovery activities against these targets [3,4,5].
DNA gyrase and topoisomerase IV inhibitors are distin-
guished from one another by their mechanisms of inhi-
bition of the enzyme machinery. A complete cycle of
catalytic activities for type II topoisomerases involves
the transduction of energy from adenosine 50-triphosphate
(ATP) hydrolysis to drive the passage of one intact DNA
strand through another DNA segment in which the phos-
phate backbone of both strands is broken and transiently
transferred to tyrosine residues on the enzyme [6,7]. In a
broad sense, inhibitors of gyrase and topoisomerase IV can
be categorized into those that block ATP binding and those
that interfere with DNA binding or DNA strand passage.
Due to the similarity between the targets, inhibitors with
these modes of inhibition are usually active against both
gyrase and topoisomerase IV. This phenomenon, known as
dual-targeting, can result in low mutation frequencies for
drug resistance, which is another valuable feature of the
type II topoisomerase targets.
ATP-site inhibitors
There has been a resurgence in recent years in the number
and variety of compounds that interfere with the ATP
hydrolysis that drives the mechanical activity of type II
topoisomerases. The prototype inhibitor that competes
with ATP as its mechanism of inhibition is novobiocin,
which contains an aminocoumarin scaffold, and is structu-
rally related to several other natural products of this class
[8]. However, despite potent antibacterial activity against
Gram-positive pathogens, aminocoumarins have been lim-
ited in therapeutic utility due to a combination of challen-
ging pharmaceutical and pharmacokinetic properties.
Through the application of structure-based drug design
and iterative screening for improved pharmaceutical and
pharmacokinetic parameters, a suite of ATP-site inhibitors
with promising clinical utility have been advanced and are
described below.
Tari et al. [9] describe a set of tricyclic compounds with a
pyrimidoindole core derived from pyrrolopyrimidines
discovered through structure-based drug design [10,11].
One compound in this series, 1 (Table 1), demonstratedwww.sciencedirect.com
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Table 1
ATP-site inhibitors
Cmpd. Structure MIC, mg/mL PPB %
bound
Efficacy model Dose
(route)
CFU/g
decrease
relative to
inoculum
Ref.
S. aur. S. pn. E. coli P. aer. M. tb.
1 (C4)
 
0.008b <0.001b 0.5b 2 NR NR I mouse thigh
E. coli
15 mg/kg
(iv)
Stasis [9]
2 (35) 0.04a 0.05a >64a NR NR 96d I mouse thigh
S. aureus
160 mg/kg
(ip)
Stasis [13]
3 (D) 2b 0.06b NR NR NR 97e I+ mouse lung
S. pneumo.
100 mg/kg
(oral)
Stasis [16]
4 (23)
 
0.03c 0.015c >8b >8b NR NR I rat thigh
S. aureus
10 mg/kg
(oral)
0.8 log10 [19]
5 (4)
 
NR NR NR NR 0.25c 93d I+ mouse lung
M. tb.
20-day
300 mg/kg
(oral)
1.1 log10 [27]
6 (AB-1)
 
0.06a 0.008a NR NR 1a NR I+ mouse lung
M. tb.
28-day
100 mg/kg
(oral)
1.5 log10 [28]
7 (17) 6a 0.6a NR NR 0.7a 79d I+ mouse lung
M. tb.
7-day
300 mg/kg
(oral)
Stasis [29]
Compound names in parentheses refer to original assignments used in listed references. Abbreviations: NR: not reported, I: immunocompromised,
I+: immunocompetent, iv: intravenous, ip: intraperitoneal.
a MIC value from 1 strain.
b MIC90 value from <30 strains.
c MIC90 value from >30 strains.
d Human plasma protein.
e Mouse plasma protein.broad-spectrum antibacterial activity, with MIC90 values
(number of strains <30) of 0.008 mg/mL versus Staphylo-
coccus aureus, and 0.5 mg/mL versus Escherichia coli. In a
larger set of 303 strains of Pseudomonas aeruginosa in-
cluding multidrug-resistant (MDR) strains, compound 1
displayed a MIC90 value of 2 mg/mL [12]. Against E. coli,
spontaneous mutation frequencies at 4 minimum
inhibitory concentration (MIC) were very low,
<1.9  1011 CFU/mL, a feature consistently reported
for recent ATP-site inhibitors and attributed to ‘dualwww.sciencedirect.com targeting’ inhibition of gyrase and topoisomerase IV. In
a mouse neutropenic thigh model of infection with E. coli,
single doses of compound 1 at 15 mg/kg administered iv
reduced tissue bacterial burden to stasis levels of inocu-
lum. Pharmaceutical and pharmacokinetic properties
were not reported for this compound. Nevertheless,
demonstration of efficacy against a Gram-negative
pathogen represents a major advancement in the promise
of ATP-site inhibitors to deliver broad-spectrum clinical
candidates.Current Opinion in Pharmacology 2014, 18:76–83
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activity of a 2-pyridylurea series of compounds engin-
eered with a goal of improved physical properties. This
team had previously reported a number of pyrrolamide-
based compounds with potent Gram-positive antibacter-
ial activity [14,15]. The optimization of the 2-pyridylurea
scaffold focused on increasing solubility, lowering plasma
protein binding, and lowering metabolic clearance. Com-
pound 2, with a S. aureus single-strain MIC value of
0.04 mg/mL, equilibrium solubility of 19 mM, human
plasma protein binding (PPB) of 96% bound, and rat
clearance value of 36 mL/min/kg (50% hepatic blood
flow) was selected for in vivo efficacy testing. In the
mouse neutropenic thigh model with S. aureus, compound
2 at 160 mg/kg and 300 mg/kg dosed ip bid resulted in a
static response and approximately 2 log10 reduction,
respectively, in CFU/g of bacterial tissue burden com-
pared to the pretreatment control.
Uria-Nickelsen et al. [16] describe a pyrimidine set of
compounds with antibacterial activity against a range of
Gram-positive pathogens. Compound 3 displayed MIC90
values of 2 mg/mL and 0.06 mg/mL in small panels (<30
strains) of S. aureus and S. pneumoniae, respectively. Kill-
ing rates were measured against these organisms and
slow, cidal behavior was noted. Mouse PPB of 97% bound
was measured for compound 3, and in an immunocom-
petent mouse lung model of S. pneumoniae infection doses
of 100 mg/kg bid oral and 300 mg/kg bid oral resulted in a
static response and >2 log10 reduction in CFU/g of bac-
terial tissue burden compared to starting inoculum.
Inhibitors with an aminobenzimidazole core have been
under investigation for several years by Grossman
et al. [17]. Acceptable pharmaceutical and pharmacoki-
netic properties appear to be a liability of this series,
specifically low solubility and high plasma protein bind-
ing. Perola et al. [18] describe the utility of measuring
bacterial susceptibility in the presence of 50% human
serum to account for protein binding effects. They
demonstrated that serum-shifted MIC values correlated
with in vivo efficacy in a rat neutropenic thigh model for
three compounds with comparable MIC values versus S.
aureus in standard testing media, similar PK parameters,
and variable levels of MIC shifts with serum. Recent
disclosures in the patent literature on the aminobenzi-
midazole class have described a prodrug approach, likely
to enhance oral bioavailability and solubility for iv admin-
istration. As summarized by Finn, compound 4 displayed
a MIC90 value of 0.03 mg/mL in a 67-strain panel of S.
aureus [19]. When tested in the presence of 50% human
serum, the MIC value for one S. aureus strain increased
eight-fold. Solubility for a crystalline form of compound 4
was reported to be <0.001 mg/mL but increased to
0.25 mg/mL for a monophosphate prodrug derivative.
Both forms of the compound were found to be efficacious
when dosed orally in an immunocompetent mouse modelCurrent Opinion in Pharmacology 2014, 18:76–83 of kidney infection with methicillin-sensitive S. aureus
(MSSA). The parent compound also displayed efficacy in
a neutropenic rat thigh model of MSSA infection. In
addition to the potential for this compound as an oral
anti-S. aureus agent, a member of the aminobenzimida-
zole class (structure not disclosed) was reported to possess
potent activity against N. gonorrhoeae, indicating possible
application of this class as an oral anti-gonococcus agent
[20].
Structurally related to the aminobenzimidazoles is the
benzothiazole urea class of ATP-site inhibitors [21,22].
An example of this class displayed a MIC90 value of
0.25 mg/mL in a 13-strain panel of S. aureus and a low
spontaneous mutation frequency of 4.5  1010 at 4
MIC. Oral bioavailability was demonstrated in a rat PK
study at 3 mg/kg, however a protein binding value of
>99% was reported and an enabling formulation contain-
ing dimethylacetamide, tetraethylene glycol, and 2-
hydroxy-propyl-b-cyclodextrin was employed for iv
administration.
The natural product kibdelomycin was initially reported
to possess Gram-positive antibacterial activity including
S. aureus, with a mechanism of inhibition similar to
aminocoumarins [23]. A new report detailed the efficacy
of kibdelomycin dosed orally in a hamster model of C.
difficile colitis, which may represent an opportunity to take
advantage of the poor systemic exposure of this molecule
and its Gram-positive antibacterial activity [24].
Another pathogen targeted by ATP site inhibitors is
Mycobacterium tuberculosis (Mtb). Mtb is unusual in that it
possesses only one type II topoisomerase, DNA gyrase.
As a result, the Mtb DNA gyrase has a distinct activity
spectrum that includes supercoiling DNA as well as
decatenation of linked strands, which allows for the
absence of topoisomerase IV in this organism. Tradition-
ally, fluoroquinolones have not been very effective for
treatment of M. tuberculosis. However, newer fluoroqui-
nolones such as moxifloxacin and gatifloxacin have shown
improved activity with the potential to shorten the
duration for tuberculosis treatment and have, thus, vali-
dated Mtb DNA gyrase as an attractive target for anti-
tubercular drug discovery. Reports of inhibitors of Mtb
gyrase can be separated into compounds structurally
related to the above-described ATP-site inhibitors and
those with novel chemotypes. Among those with novel
chemotypes are the aminopyrazinamides [25], which
displayed specificity for Mtb GyrB over E. coli GyrB,
and the naphthoquinones [26], which are a novel class
of non-competitive ATPase inhibitors targeting Mtb
GyrB. However, both of these series have yet to demon-
strate successful in vivo efficacy.
The pyrrolamide class is one example of a series under
investigation for both S. aureus and Mtb indications.www.sciencedirect.com
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supercoiling activity of Mtb DNA gyrase with IC50 values
of <5 nM, which translated to a MIC90 value of 0.25 mg/
ml against 99 drug-resistant clinical isolates of M.
tuberculosis. The frequency of isolating spontaneous
resistant mutants was 106 to 108 CFU/mL and com-
pound 5 was tested for in vivo efficacy in mouse models of
acute and chronic M. tuberculosis infection. In the acute
20-day model, a dose of 300 mg/kg administered orally for
20 days resulted in a 1.1 log10 reduction in lung CFU/mL.
The aminobenzimidazole urea compound 6 is another
potent inhibitor of Mtb GyrB with MIC values of 0.3–
2 mg/ml against a selected set of susceptible and drug-
resistant Mtb strains [28]. Interestingly, these compounds
demonstrated time-dependent bactericidal activity, in
contrast to the bacteriostatic effect of novobiocin. Spon-
taneous mutation frequencies ranged from 106 to
107 CFU/mL, and the higher frequencies for compounds
5 and 6 may be a consequence of the single DNA gyrase
target in Mtb and thus a lack of dual target potential. In a 28-
day murine lung model of TB, compound 6 demonstrated a
dose-dependent reduction in lung CFU counts (1.5 log10
decrease at 100 mg/kg dosed orally).
Lastly, structurally similar to the aminobenzimidazoles
are a series of thiazolopyridone ureas, with reported MIC
values of <1 mg/mL versus a single strain of Mtb [29,30].
Compound 7 displayed a MIC value of 0.7 mg/mL and a
human plasma protein binding value of 79% bound.
When dosed orally in mice at 150 mg/kg in a 7-day lung
model, the compound showed a dose response and a
0.5 log10 CFU/mL decrease versus the pre-treatment
control.
The examples above highlight the progress being made
towards clinical candidates targeting the ATP site of
gyrase/topoisomerase IV. Recurring issues of poor solu-
bility and high plasma protein binding appear to be
unavoidable features of inhibitors of the ATP binding
site, but signs of progress to combat these liabilities
appear in recent efforts. Promising, too, is the demon-
stration of in vivo efficacy for numerous inhibitors, how-
ever little information has been presented for the
relationship between pharmacokinetics and pharmacody-
namics (PK-PD) to allow comparison to fluoroquinolones
or drugs of other classes. Of note is the description of slow
cidal in vitro killing behavior for ATP-site inhibitors,
which may be an inherent trait of this mechanistic class.
As a consequence, a key unanswered question is whether
higher PK-PD magnitudes for efficacy are required for
ATP-site inhibitors than for fluoroquinolones, which are
rapidly cidal in vitro and in vivo.
Catalytic site inhibitors
Decades after their initial discovery, the fluoroquinolone
class of type II topoisomerase inhibitors still remainwww.sciencedirect.com well-represented in the clinical development pipeline
[31]. Reflecting this wealth of compounds in develop-
ment, there has been little activity in reporting new
fluoroquinolones in preclinical or early clinical develop-
ment that possess differentiated features. However,
exciting non-fluoroquinolone molecules are progressing
into clinical development, as detailed below.
Numerous groups of investigators have reported on a
series of inhibitors that bind near the catalytic center
of gyrase and topoisomerase IV, but are mechanistically
and microbiologically distinct from fluoroquinolones.
Due to the variety in core chemical structures for these
compounds, the name of this class has not yet been
defined by a chemical scaffold, but instead the class is
named ‘Novel Bacterial Topoisomerase Inhibitors’
(NBTIs). NBTIs have been shown to bind to type II
topoisomerases during a different phase of the catalytic
cycle from fluoroquinolones. Both bind through inter-
actions to the protein–DNA complex, but in contrast to
fluoroquinolones that bind to the enzymes with its cat-
alytic tyrosines engaged with the broken double-stranded
DNA, NBTIs bind to the enzymes in the presence of
intact, unbroken DNA [32].
Published NBTIs display potent broad-spectrum anti-
bacterial activity (including fluoroquinolone-resistant
strains), reasonable non-rodent PK, and low plasma
protein binding [3,33]. Inhibition of the human cardiac
potassium channel hERG is a liability of this series and
reducing hERG inhibition has been the focus of recent
lead optimization efforts [34]. Miles et al. [35] published
a report of one NBTI, GSK966587 (Table 2), which
possessed single-strain MIC values of 0.12 mg/mL versus
S. pneumoniae and S. aureus and a hERG IC50 of 310 mM.
Renal clearance in dog and monkey was low to moderate,
protein binding was <25% in non-rodents, and >50% oral
bioavailability was seen at a 5 mg/kg dose. In an immu-
nocompetent mouse model of S. pneumoniae lung infec-
tion, GSK966587 dosed iv at 50 mg/kg bid resulted in a
2 log10 reduction in CFU/g of tissue burden. This com-
pound was advanced into preclinical toxicology studies
and in a 14-day dog study hepatic portal tract lesions were
observed. A mechanistic explanation for this finding was
not given, however subsequent effort by these investi-
gators to test additional compounds for toxicological
findings in multi-day rat and dog studies led to the
discovery of GSK2140944. In large-panel susceptibility
testing, GSK2140944 displayed MIC90 values of 0.25 mg/
mL and 0.5 mg/mL versus S. pneumoniae and S. aureus,
respectively [36]. Activity against cardiac channels was
not reported, however the compound has progressed
through phase I studies using oral dosing with no clini-
cally significant changes in ECG cardiac parameters
noted up to a top dose of 3000 mg [37]. A Phase II trial
treating skin and skin structure infections caused by S.
aureus has been started [38]. An additional possible utilityCurrent Opinion in Pharmacology 2014, 18:76–83
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Table 2
Catalytic site inhibitors
Cmpd. Structure MIC, mg/mL Human
PPB %
bound
hERG
IC50
(mM)
Efficacy
model
PK-PD
index
PK-PD
magnitude
for stasisd
Ref.
S. aur. S. pn. E. coli P. aer. N. gon.
GSK966587 0.13a 0.13a NR NR NR 22 310 I+ mouse
lung
S. pneumo.
NR NR [35]
GSK2140944 0.5c 0.25c 4c NR NR NR 1400 NR NR NR [3,36,
37]
AZD9742 (7c) 0.06a 0.13a 4a >8a NR 25 233 I mouse
thigh
S. aureus
fAUC/MIC 36 [40]
NBTI 5463 1a NR 2b 2b NR 27 >333 I mouse
thigh
P. aerug.
fAUC/MIC 16 [41]
AZD0914 0.25c 0.25c NR NR 0.12c NR NR I mouse
thigh
S. aureus
fAUC/MIC 66 [3,46,
47]
Compound names in parentheses refer to original assignments used in listed references. Abbreviations: NR: not reported, I: immunocompromised,
I+: immunocompetent.
a MIC value from 1 strain.
b MIC90 value from <30 strains.
c MIC90 value from >30 strains.
d Stasis relative to starting inoculum or pretreatment control.of GSK2140944 is as a treatment for biothreat pathogens
such as B. anthracis and F. tularensis [39].
Another advanced compound from the NBTI scaffold
was published by Reck et al. [40] whose optimization
plan was focused on reducing hERG inhibition.
AZD9742 displayed single-strain MIC values of
0.12 mg/mL and 0.06 mg/mL versus S. pneumoniae and
S. aureus, respectively, and a hERG IC50 of 233 mM. The
compound was 75% bound to human plasma protein,
displayed high rat clearance but low dog clearance, and
was bioavailable at 60% in dog at a 10 mg/kg dose. In an
immunocompromised mouse model of thigh infection
with S. aureus, AZD9742 dosed ip once a day at 60 mg/
kg resulted in 1.5 log10 CFU/g reduction in thigh bacterial
burden. The PK-PD index associated with efficacy was
determined to be free AUC/MIC (fAUC/MIC), and a
fAUC/MIC magnitude of 36 was required for a static
response in the immunocompromised mouse thigh
model. Data with AZD9742 in a guinea pig model of
cardiac repolarization did not show a difference from
vehicle at 30 mM free drug concentration. AZD9742
was reported to have entered phase I trials and completed
studies in 2012 [38].
Most NBTI series compounds have been positioned for
the treatment of Gram-positive infections, however
Dougherty et al. reported on a derivative with promisingCurrent Opinion in Pharmacology 2014, 18:76–83 Gram-negative activity [41]. NBTI 5463 displayed small-
panel MIC90 values of 2 mg/mL versus both P. aeruginosa
and E. coli, as well as a single-strain S. aureus MIC value of
1 mg/mL. Antibacterial activity versus P. aeruginosa was
maintained against MDR isolates. In P. aeruginosa, a
spontaneous mutation frequency of 5  108 CFU/mL
at 4 MIC was reported, and first-step mutants appeared
exclusively in a negative regulator of an efflux pump
system. Metabolic clearance was high in rat but moderate
in dog, human PPB was 27% bound, and low bioavail-
ability seen in rat. Inhibition of the hERG channel was
reported to be >333 mM. In an immunocompromised
mouse thigh model of infection with E. coli and P.
aeruginosa, doses of NBTI 5463 at 200 mg/kg adminis-
tered ip bid resulted in >2 log10 reduction in CFU/g thigh
tissue. The fAUC/MIC magnitude for stasis in the mouse
P. aeruginosa model was calculated to be 16.
Additional reports of NBTI series compounds with Gram-
positive antibacterial activity and efficacy in rodent
models of S. aureus infection have been reported recently
[42–44], however these reports do not contain information
on the PK-PD properties of the compounds nor their
effects on cardiac parameters in in vivo models.
In addition to the NBTI scaffold, another series of inhibi-
tors that may interfere with the action of the DNA strand
passage machinery are spiropyrimidinetriones containingwww.sciencedirect.com
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One member of this class, AZD0914, has been positioned
for the treatment of infections caused by N. gonorrhoeae
[46]. Using animal efficacy data from the neutropenic
mouse thigh model of S. aureus as a surrogate, an estimated
human therapeutic oral dose of 800–1600 mg was calcu-
lated to provide >95% target attainment for efficacy
against N. gonorrhoeae [47,48]. Based on its promise as
an oral anti-gonococcal agent AZD0914 has entered and
completed phase I clinical trials [38].
Other type II topoisomerase inhibitors
Beyond the above-mentioned ATP site and catalytic site
inhibitors, additional modes of inhibition have been dis-
covered for type II topoisomerases and represent oppor-
tunities for new therapeutics. In this vein, Collin et al. [49]
described a finding that truncated fragments of the pep-
tide-based inhibitor Microcin B17 retained gyrase super-
coiling inhibition activity and stabilized the enzyme-
DNA cleavage complex; however inhibition of E. coli
growth was not achieved. Another series with a distinct
mode of inhibition are the gyramides, which were shown
not to stabilize the enzyme–DNA cleavage complex and
which display weak Gram-positive antibacterial activity
[50]. Rajendram et al. reported that a gyramide appeared
to selectively inhibit the catalytic activity of gyrase, but
not topoisomerase IV [51], which is an unusual finding, as
other inhibitor classes usually display measurable dual
target activity for both gyrase and topoisomerase IV.
Topoisomerase I inhibitors
Besides the type II topoisomerases, most bacterial patho-
gens possess an additional essential topoisomerase, topoi-
somerase I (Topo I). Topo I is architecturally and
mechanistically distinct from gyrase and topoisomerase
IV, and as such represents an attractive target for the
discovery of novel antibacterial chemotypes. Duan
et al. described a halogenated anthraquinone derived from
emodin, an herbal medicine component [52]. One of the
haloemodins displayed inhibitory enzymatic activity
against DNA gyrase and topoisomerase I, but was se-
lective relative to the human topoisomerases I and IIa.
Antibacterial activity was reported to be <32 mg/mL
versus a panel of S. aureus isolates and one compound
displayed efficacy when dosed topically in a rabbit model
of S. aureus keratitis.
Conclusions
Through the dedicated effort of numerous investigators,
new antibacterial agents targeting topoisomerases con-
tinue to be discovered and disclosed. Compared to other
human diseases, the clinical development of antibacterial
agents has the advantage of robust animal models with a
proven track record of predicting efficacy in human
clinical trials. As outlined in this review, multiple new
inhibitors with distinct mechanisms of inhibition and
efficacy in animal models of infection were reported inwww.sciencedirect.com recent years. However, to achieve their therapeutic
benefit antibacterials usually require high human doses
that can engender issues with drug tolerability and for-
mulation. A more complete assessment of these emerging
topoisomerase inhibitors will come with disclosures of
their safety and toxicological properties. For the ATP-site
inhibitors in particular, description of the PK-PD indices
and magnitudes required for efficacy in preclinical models
would enable a clearer evaluation of the potential of drug
candidates with this mechanism. Among the molecules
described as catalytic site inhibitors of gyrase/topoisome-
rase IV, promising PK-PD analysis and preclinical toxi-
cology screening has led to the advancement of several
compounds into phase I and phase II clinical trials.
Additional disclosures of the results from these safety
and efficacy studies are eagerly anticipated in the quest
for new topoisomerase inhibitors as valuable medicines
for the treatment of bacterial infections.
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